Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Rinke A, et al. Among authors: harder j. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704057 Clinical Trial.
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C. Drevs J, et al. Among authors: harder j. J Clin Oncol. 2007 Jul 20;25(21):3045-54. doi: 10.1200/JCO.2006.07.2066. J Clin Oncol. 2007. PMID: 17634482 Clinical Trial.
[Esophageal carcinoma: non-surgical therapy].
Geissler M, Schwacha H, Eggstein S, Usadel H, Harder J, Opitz O, Arnold C, Grimm CF, Blum HE. Geissler M, et al. Among authors: harder j. Praxis (Bern 1994). 2004 Dec 1;93(49):2057-64. doi: 10.1024/0369-8394.93.49.2057. Praxis (Bern 1994). 2004. PMID: 15630988 Review. German.
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E. Kullmann F, et al. Among authors: harder j. Oncology. 2011;81(1):3-8. doi: 10.1159/000330194. Epub 2011 Sep 2. Oncology. 2011. PMID: 21894049 Clinical Trial.
[Cholangiocarcinoma].
Harder J, Blum HE. Harder J, et al. Praxis (Bern 1994). 2002 Aug 21;91(34):1352-6. doi: 10.1024/0369-8394.91.34.1352. Praxis (Bern 1994). 2002. PMID: 12233266 Review. German.
Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R. Kuhlmann JB, et al. Among authors: harder j. Eur J Gastroenterol Hepatol. 2012 Apr;24(4):437-43. doi: 10.1097/MEG.0b013e3283502241. Eur J Gastroenterol Hepatol. 2012. PMID: 22261548 Clinical Trial.
522 results